KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Debt: 2017-2019

Historic Total Debt for Xenon Pharmaceuticals (XENE) over the last 2 years, with Dec 2019 value amounting to $15.5 million.

  • Xenon Pharmaceuticals' Total Debt rose 3.55% to $15.7 million in Q1 2020 from the same period last year, while for Mar 2020 it was $15.7 million, marking a year-over-year increase of 3.55%. This contributed to the annual value of $15.5 million for FY2019, which is N/A change from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Total Debt stood at $15.5 million for FY2019, which was up 128.38% from $6.8 million recorded in FY2017.
  • In the past 5 years, Xenon Pharmaceuticals' Total Debt ranged from a high of $15.5 million in FY2019 and a low of $6.8 million during FY2017.
  • Over the past 2 years, Xenon Pharmaceuticals' median Total Debt value was $11.2 million (recorded in 2017), while the average stood at $11.2 million.